Canadian Respiratory Journal / 2018 / Article / Tab 1 / Review Article
Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis Table 1 Characteristics of included studies.
Author Year J Drug Male (%) Mean age (years) FEV1 (% predicted) Current smokers (%) Treatment duration (weeks) Aaron et al. [22 ] 2007 7 SFC versus SAL 57.9 67.5 ± 8.9 39.4 ± 11.9 32.4 52 57.4 67.6 ± 8.2 38.0 ± 13.1 24.3 Burge et al. [23 ] 2000 5 FP versus placebo 75 63.7 ± 7.1 50.3 ± 14.9 36.4 156 74.2 63.8 ± 7.1 50.0 ± 14.9 39.2 Calverley et al. [24 ] 2003 5 SFC versus SAL; FP versus placebo 75 62.7 ± 8.7 44.8 ± 14.7 52 52 70 63.2 ± 8.6 44.3 ± 13.8 51 70 63.5 ± 8.5 45 ± 13.6 53 75 63.4 ± 8.6 44.2 ± 13.7 47 Calverley et al. [25 ] 2007 6 SFC versus SAL; FP versus placebo 75 65 ± 8.3 44.3 ± 12.3 43 156 76 65.1 ± 8.2 43.6 ± 12.6 43 75 65 ± 8.4 44.1 ± 12.3 43 76 65 ± 8.2 44.1 ± 12.3 43 Ferguson et al. [26 ] 2008 7 SFC versus SAL 58.3 64.9 ± 9.0 39.8 ± 13.9 40 52 52.0 65.0 ± 9.1 50.6 ± 15.4 38 FLTA3025 [41 ] 2000 5 FP versus placebo 66 63.3 ± 10 NA NA 24 72 65.2 ± 8.7 Hanania et al. [27 ] 2003 7 SFC versus SAL 61 63 ± NA 41 ± 11 43 24 58 64 ± NA 42 ± 12 51 Kardos et al. [28 ] 2007 4 SFC versus SAL 74 63.8 ± 8.3 40.4 ± 8.9 49.7 52 77.6 64 ± 8.2 40.3 ± 8.5 49.9 Lofdahl et al. [15 ] 2007 5 Budesonide versus placebo 73.5 52.5 ± 7.5 76.8 ± 12.4 39.4 156 72.2 52.4 ± 7.7 76.9 ± 13.2 39.2 Paggiaro et al. [29 ] 1998 5 FP versus placebo 99 62 ± NA 59 ± 18 49 24 78 64 ± NA 55 ± 17 49 Rennard et al. [45 ] 2009 6 Budesonide/FOR versus placebo 62.5 63.2 ± 8.9 33.8 ± 11.4 34.8 52 65.3 62.9 ± 9.1 35.5 ± 11.9 39.5 SCO100250 [40 ] 2007 6 SFC versus SAL 51 65.4 ± NA NA NA 52 57 65.3 ± NA SCO100470 [42 ] 2005 6 SFC versus SAL 78.3 63.5 ± 9.3 NA 42 24 77.2 63.7 ± 9.0 44 SCO40041 [43 ] 2007 5 SFC versus SAL 59.7 65.4 ± 8.4 NA NA 156 62.7 65.9 ± 9.5 SFCT01/SCO30002 [44 ] 2005 5 FP versus placebo 83.9 64.6 ± 8.7 NA NA 52 80 65.7 ± 9.0 Tashkin et al. [46 ] 2008 4 Budesonide/FOR versus FOR 67.9 63 ± NA 33.7 ± 11.8 40.8 26 65.5 64 ± NA 33.6 ± 11.3 38.4 Budesonide versus placebo 67.6 63 ± NA 33.5 ± 10.8 40.0 69.0 63 ± NA 34.6 ± 10.5 36.0 Vestbo et al. [47 ] 1999 5 Budesonide versus placebo 58.6 59.0 ± 8.3 86.2 ± 20.6 75.9 156 62.1 59.1 ± 9.7 86.9 ± 21.1 77.2 Wouters et al. [30 ] 2005 4 SFC versus SAL 73 63 ± 7.9 47.4 ± 13.9 39 52 75 64 ± 7.7 48.2 ± 12.9 35 Boscia et al. [31 ] 2012 4 FF/VI versus placebo 46 57.9 ± 9.2 49.8 ± 10.6 83 4 Vestbo et al. [32 ] 2009 4 FP versus placebo 75 64.8 ± NA 44.7 ± NA 43 144 77 64.9 ± NA 44.4 ± NA 42 SFC versus SAL 75 64.9 ± NA 44.8 ± NA 43 77 64.8 ± NA 44.1 ± NA 43 Vestbo et al. [39 ] 2016 6 FF versus placebo 74 65 ± 8 59.6 ± 6.1 47 152 75 65 ± 8 59.7 ± 6.1 47 FF/VI versus VI 76 65 ± 8 59.7 ± 6.1 45 75 65 ± 8 59.7 ± 6.1 47 Kerwin et al. [34 ] 2013 4 FF versus placebo 64 62.7 ± 9.5 41.5 ± 13.13 54 24 68 62.1 ± 8.8 42.4 ± 12.80 54 FF/VI versus VI 67 62.3 ± 8.5 42.3 ± 12.74 54 68 63.4 ± 9.6 44.5 ± 12.78 54 Dransfield et al. [3 ] 2013 6 FF/VI versus VI 57.3 63.6 ± 9.1 45.7 ± 12.9 NA 52 58.4 63.6 ± 9.4 44.3 ± 13.2 Calverley et al. [35 ] 2010 7 SFC versus SAL 75 65.0 ± 8.3 NA 43 144 76 65.2 ± 8.2 43 FP versus placebo 75 65.1 ± 8.4 43 76 65.1 ± 8.1 43 Martinez et al. [16 ] 2013 5 FF/VI versus VI 71 61.9 ± 8.8 48.1 ± 12.85 53 24 74 61.2 ± 8.6 48.5 ± 12.89 55 FF versus placebo 74 61.8 ± 8.3 48.4 ± 12.17 56 74 61.9 ± 8.1 48.3 ± 12.71 53 Donohue et al. [36 ] 2015 5 FSC versus UMEC/VI 69 63.0 ± 8.91 48.3 ± 10.82 41 12 72 62.5 ± 9.05 48.6 ± 10.71 45 Singh et al. [37 ] 2015 4 FSC versus UMEC/VI 71 61.4 ± 8.06 51.1 ± 10.50 61 12 73 61.8 ± 7.94 50.2 ± 10.85 57 Zheng et al. [17 ] 2015 5 FF/VI versus placebo 93 65.1 ± 9.19 49.6 ± 13.19 52 24 90 64.7 ± 8.78 48.6 ± 13.39 56 Wedzicha et al. [48 ] 2014 5 BDP/FOR versus FOR 69 64.6 ± 8.6 41.9 ± 6.0 39 48 69 63.9 ± 8.6 41.6 ± 6.0 40 Vogelmeier et al. [38 ] 2013 7 SFC versus QVA149 71.6 63.4 ± 7.7 60.0 ± 10.7 48.1 48 70.2 63.2 ± 8.2 60.5 ± 10.5 47.7 Vestbo et al. [33 ] 2016 7 FF/VI versus placebo 50 67 ± 10 NA 45 144 48 67 ± 10 47
The quality (Q) of each study was based on the Jadad scoring system. J: Jadad score; FP: fluticasone propionate; SAL: salmeterol xinafoate; SFC: combination of salmeterol xinafoate and fluticasone propionate; BDP: beclomethasone dipropionate; FOR: formoterol; TIO: tiotropium; UMEC: umeclidinium; QVA149: combination of indacaterol (a long-acting β 2 agonist) with glycopyrronium (a long-acting muscarinic antagonist) as a dual bronchodilator; FF: fluticasone furoate; VI: vilanterol; NA: not applicable.
